SA Pharmaceutical Journal (SAPJ) official mouthpiece of the Pharmaceutical Society of South Africa (PSSA). SAPJ is aimed at the continuing professional development of the South African pharmacist as a clinical pharmaceutical care practitioner in a community or hospital pharmacy environment or in a regulatory position in the pharmaceutical industry. The journal provides specific clinical reviews on self-medication topics (symptomatic therapy), information on prescription medication (therapy in clinical context) and provides the pharmacists with essential information for referring customers for early medical attention should it be required. Pharmacovigilance – ensuring the safe and appropriate administration and use of medication and reporting of serious adverse events or other adverse drug reactions – is strongly advocated in SAPJ. The SAPJ further supports pharmacists to transform the pharmacy in an accessible, basic primary health care facility for preventing and treating PHC conditions through diagnosis, screening and treatment.

Jardiance Declared Best International Pharmaceutical Product 2018

Jardiance Declared Best International Pharmaceutical Product 2018 Boehringer Ingelheim’s sodium-glucose co-transporter 2 (SGLT-2) inhibitor, Jardiance (empagliflozin), has been announced winner of the 2018 Prix Galien International Award in the category “Best...

Maternal mortality – Fact Sheet

Maternal mortality - Fact SheetMSD for Mothers     Global statistics1 • Every day, approximately 830 women die from preventable causes related to pregnancy and childbirth. • 99% of all maternal deaths occur in developing countries. • Maternal mortality is...

CIPLA LAUNCHES NEW TRIPLE-COMBINATION ANTIRETROVIRAL DRUG, REYDIN

Ahead of World Aids Day and as part of its continued commitment to ensuring access to quality, affordable antiretrovirals (ARV), Cipla is launching its new triple-combination ARV treatment for HIV in South Africa.

Empagliflozin proven to improve clinical outcomes in real world practice across a broad spectrum of cardiovascular risk

The most recent 2018 treatment recommendations from the American Diabetes Association are that, after considering drug specific and patient factors, treatment for people with atherosclerotic cardiovascular disease (ASCVD) should begin with lifestyle management and metformin and subsequently incorporate an agent proven to reduce major adverse cardiovascular events and/or cardiovascular mortality.

Skin protection range, Dexeryl, receives Allergy Foundation’s seal of approval

Partnership brings established international brand to South African consumers with complementary barrier and cleansing presentations for dry skins.

Wildcard SSL